home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Courses and Workshops  

Regulatory Affairs: Part I: The IND Phase and Part II: The NDA Phase

  March 06, 2011  
Hyatt Regency Boston , Boston, MA
Aug 8 2011 8:30AM - Aug 12 2011 2:30PM

Learn how to apply regulatory concepts to ensure compliant IND submissions to the FDA. Gain insight into the regulatory background of the NDA, preparing an NDA, and postapproval activities. The course focuses on drug and well characterized biological products and not the regulatory process for devices, generic products, or traditional biologics.

What you will learn
• Overview of the drug development process
• The IND process
• Quality assurance in drug development (GXPs)
• FDA’s actions on the original IND and amendments
• Activities and submissions after the original IND
• Procedures for reporting adverse events (AEs)
• Overview and roles and responsibilities of FDA
• NDA in CTD format
• Regulatory compliance and FDA inspections
• Post-approval regulatory requirements for NDAs
• Regulatory requirements for prescription drug/biologics labeling
• Regulatory requirements for prescription drug/biologics advertising
• How to interact with the FDA

Event Code:
Organized by: DIA
Invited Speakers: See web site for speaker information
Deadline for Abstracts: Call contact
Registration: For detailed program information including faculty and topics, please contact:
Susan Mazak
Tel. +1-215-442-6183 
E-mail: susan.mazak@diahome.org
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.